FDAapproval84% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · Hormone Receptor-positive Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer